Are We Getting Closer to Personalized Ketamine Therapies?
Last reviewed and updated: August 16, 2026.
Key Takeaways
| What it means | Personalized ketamine therapy tailors dose, route, frequency, and support to the individual, rather than a one-size-fits-all protocol. |
| What research explores | Scientists are studying biomarkers, metabolism differences, genetics, and brain-activity markers to predict who responds and how to individualize care. |
| Where it stands | Personalization is a promising research direction, not yet routine. Most clinics still use standardized protocols and adjust by response. |
| What clinics do now | Dosing is weight-based, and providers adjust dose and frequency based on how a patient responds and tolerates treatment, not validated biomarkers. |
| The measured view | No biomarker reliably predicts ketamine response in practice yet. Progress is real, but true personalization is still developing. |
A recent study published in Translational Psychiatry explores the personalized use of ketamine and esketamine for individuals with treatment-resistant depression (TRD). The research, conducted by Gustavo C. Medeiros and colleagues, delves into how these medications can be tailored to meet the unique needs of patients who have not responded to traditional antidepressant therapies.
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
Understanding Treatment-Resistant Depression
Depression affects millions worldwide, but standard treatments like antidepressants and psychotherapy don’t work for everyone. When at least two different treatments fail, the condition is termed treatment-resistant depression. This poses significant challenges for both patients and healthcare providers.
The study offers significant insights into the personalized application of ketamine and esketamine for treatment-resistant depression (TRD).
Here’s a Summary of the Findings:
| Key Findings | Details |
|---|---|
| Rapid Antidepressant Effects | Both ketamine and esketamine can alleviate depressive symptoms within hours to days, offering faster relief compared to traditional antidepressants. |
| Personalized Treatment Approaches | Tailoring treatments based on individual factors, such as genetic makeup, medical history, and specific depression symptoms, can enhance effectiveness and reduce side effects. |
| Safety Considerations | Due to potential side effects like increased blood pressure and dissociative symptoms, administering these treatments in controlled settings is crucial for patient safety. |
| Implications for Future Research | The study underscores the potential of personalized medicine in addressing complex conditions like TRD, paving the way for more individualized and effective treatments. |
Ketamine and Esketamine: New Hope
Ketamine, originally an anesthetic, has shown rapid antidepressant effects in low doses. Esketamine, a derivative of ketamine, has been approved by the FDA for TRD. Unlike traditional antidepressants that may take weeks to work, these medications can alleviate depressive symptoms within hours to days.
Personalizing Treatment
The study emphasizes the importance of tailoring ketamine and esketamine treatments to individual patients. Factors such as genetic makeup, medical history, and specific depression symptoms can influence how a person responds to these treatments. By considering these factors, healthcare providers can optimize treatment effectiveness and minimize potential side effects.
Safety and Monitoring
While promising, ketamine and esketamine treatments require careful monitoring due to potential side effects like increased blood pressure and dissociative symptoms. The study highlights the necessity of administering these treatments in controlled settings, ensuring patient safety and the best possible outcomes.
Looking Ahead
This research underscores the potential of personalized medicine in treating complex conditions like TRD. By customizing treatments to individual needs, there’s hope for more effective and faster relief for those who have struggled with depression for years.
In summary, the study by Medeiros and colleagues provides valuable insights into the personalized use of ketamine and esketamine for TRD. It opens avenues for more effective, individualized treatments, bringing hope to those who have long suffered from depression.
Personalized Ketamine Therapy in 2026
Personalized, or precision, ketamine therapy means tailoring dose, route, frequency, and support to the individual rather than using one fixed protocol. Ketamine helps many people with depression, but it does not work for everyone. Providers cannot always predict who will benefit before treatment begins. The goal of this research is to answer two questions: who is likely to respond, and how should each person be treated for the best result? Matching care to the individual could improve outcomes and reduce wasted time and cost.
Researchers are studying several ways to individualize ketamine treatment. One direction is biomarkers that may predict response, including inflammatory markers and BDNF, a protein tied to brain plasticity. Another looks at how people metabolize ketamine, since active metabolites may shape the effect. Genetics may also influence who benefits, and brain-activity or imaging markers could signal an early response. Dosing is already weight-based, and that is one simple form of personalization clinics use today.
A measured view matters here. Personalization is a promising research direction, not yet routine practice. Most clinics still use fairly standardized protocols, such as 0.5 mg/kg given intravenously, and adjust based on response and tolerability rather than validated biomarkers. No biomarker reliably predicts ketamine response in clinical practice yet. The realistic picture is real progress alongside real limits, and the field keeps moving toward true personalization.
Frequently Asked Questions
- What is personalized ketamine therapy?
- Personalized, or precision, ketamine therapy means tailoring the dose, route, frequency, and support to the individual patient rather than using a single fixed protocol. The goal is to match treatment to the person, improving response and reducing wasted time and cost. It is an active research direction more than a routine clinical practice today.
- Can doctors predict who will respond to ketamine?
- Not reliably yet. Researchers are studying biomarkers such as inflammatory markers and BDNF, differences in metabolism, genetics, and brain-activity markers to predict response. So far, no biomarker reliably predicts who will respond to ketamine in clinical practice, so providers still rely on trying treatment and adjusting based on how a patient responds.
- How do clinics personalize ketamine treatment now?
- In practice, personalization is mostly weight-based dosing plus adjusting the dose and frequency based on how a patient responds and tolerates treatment. Providers also consider a patient’s history, other medications, and goals. This is real but limited personalization, and it is different from the biomarker-guided precision that researchers are working toward.
- Is personalized ketamine therapy available today?
- Only in a limited sense. Clinics individualize dose and frequency based on response, but validated biomarker-guided personalization is not yet routine. The research is promising, and the field is moving toward more precise, individualized ketamine treatment, but a measured view is that true personalization is still developing rather than widely available.
